20
207940.KO Samsung Biologics Co Ltd
- Market cap
- KRW 70.8T
- P/E
- 37.6x
- P/B
- 8.08x
- ROE
- 21.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 207940.KO undervalued?
Graham numberThe Graham number of Samsung Biologics Co Ltd cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Samsung Biologics Co Ltd fundamental analysis
No fundamental analysis for Samsung Biologics Co Ltd yet.
Samsung Biologics Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Samsung Biologics Co Ltd
Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing, commercializing, distributing, and selling of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. Its development services include late discovery, cell line development, process development, analytical development, and non-GMP / CGMP manufacturing. The company also offers aseptic filling, lyophilization, finishing, cold chain storage and shipping, …
Full company profileSamsung Biologics Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Samsung Biologics Co Ltd annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 295B | 465B | 536B | 702B | 1.16T | 1.57T | 3.00T | 3.69T | 3.50T | 4.56T | 5.16T |
| Gross Profit | 26.5B | 132B | 145B | 192B | 416B | 726B | 1.47T | 1.80T | 1.71T | 2.52T | 2.76T |
| Operating Income | -30.4B | 66.0B | 55.7B | 91.7B | 293B | 537B | 984B | 1.11T | 1.32T | 2.07T | 2.33T |
| EBITDA | - | -40.4B | 410B | 314B | 426B | 738B | 1.38T | 1.69T | 2.02T | 2.78T | 2.90T |
| Net Income | -177B | -97.0B | 224B | 203B | 241B | 394B | 798B | 858B | 1.08T | 1.78T | 1.80T |
| EPS | - | -1,466 | 3,387 | 3,067 | 3,642 | 5,886 | 11,213 | 12,051 | 15,221 | 38,546 | 38,923 |
| Balance Sheet | |||||||||||
| Total Assets | 7.53T | 7.18T | 5.98T | 5.91T | 6.42T | 7.97T | 16.6T | 16.0T | 17.3T | 11.1T | 12.7T |
| Total Liabilities | 3.45T | 3.21T | 1.82T | 1.56T | 1.83T | 2.98T | 7.60T | 6.22T | 6.43T | 3.61T | 4.29T |
| Shareholders' Equity | 4.08T | 3.98T | 4.16T | 4.35T | 4.60T | 4.99T | 8.98T | 9.83T | 10.9T | 7.45T | 8.36T |
| Cash & Short-term Investments | 230B | 358B | 17.6B | 125B | 28.9B | 47.4B | 891B | 368B | 391B | 149B | 289B |
| Cash Flow | |||||||||||
| Operating Cash Flow | -62.7B | 150B | -33.0B | 10.2B | 202B | 455B | 953B | 1.67T | 1.66T | 2.25T | 2.78T |
| Capital Expenditure | 168B | 494B | 279B | 193B | 140B | 406B | 957B | 1.11T | 1.38T | 1.48T | 381B |
| Free Cash Flow | - | -355B | -317B | -171B | 53.5B | 33.4B | -56.2B | 561B | 282B | 773B | 2.40T |
| Ratios | |||||||||||
| ROE | -4.3% | -2.4% | 5.4% | 4.7% | 5.2% | 7.9% | 8.9% | 8.7% | 9.9% | 23.9% | 21.5% |
| ROA | -2.3% | -1.4% | 3.7% | 3.4% | 3.8% | 4.9% | 4.8% | 5.3% | 6.2% | 16.1% | 14.2% |
| Net Profit Margin | -60.0% | -20.9% | 41.8% | 28.9% | 20.7% | 25.1% | 26.6% | 23.2% | 31.0% | 39.2% | 34.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Samsung Biologics Co Ltd dividends
Samsung Biologics Co Ltd has not paid dividends in the last 9 fiscal years.
Last stock split: 0.650391:1 on Oct 30, 2025.
Who owns Samsung Biologics Co Ltd
- Insiders 74.36%
- Institutions 16.32%
- Public & others 9.32%
- Shares outstanding 46.6M
- Free float 11.8M
Samsung Biologics Co Ltd company profile
- Company name
- Samsung Biologics Co Ltd
- Ticker
- 207940.KO
- ISIN
- KR7207940008
- Exchange
- Korea Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 5,326
- Fiscal year end
- December
- Address
- 300, Songdo bio-daero, Incheon, South Korea
- Phone
- 82 3 2455 3114
- Website
- samsungbiologics.com
About Samsung Biologics Co Ltd
Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing, commercializing, distributing, and selling of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. Its development services include late discovery, cell line development, process development, analytical development, and non-GMP / CGMP manufacturing. The company also offers aseptic filling, lyophilization, finishing, cold chain storage and shipping, and regulatory support services; and quality services and analytical testing services, such as IPC and release testing, stability study and testing, environmental monitoring, biosafety testing, as well as manufactures drug substance. In addition, it engages in the development and manufacture of antibody-drug conjugates and mRNA products. The company was founded in 2011 and is headquartered in Incheon, South Korea.
Samsung Biologics Co Ltd management
10- Mr. John Chongbo RimCEO, President & Chairman of Board · born 1961
- Dr. Kun Lo Ph.D.Executive VP, Head of EPCV Center & Director · born 1963
- Mr. Seung ho RyuEVP, CFO, Head of Business Support Center & Director · born 1968
- Mr. Kevin SharpEVP, Head of Sales & Operations Department
- Mr. Kyuho LeeExecutive VP, Head of People Center, & Chief Human Resource Officer
- Mr. James J. ChoiExecutive VP, Head of CDO Development Center & Head of Sales Center · born 1967
- Mr. Heekyun LimVP & Head of Business Consulting Team · born 1975
- Sojeong LeeVP & Head of Regulatory Affairs
- Ms. Heejeong KimVP & Head of Drug Substance Department
- Mr. Sangmyung LeeVP & Head of CDO Development